Smith & Nephew SNATS, Inc. (NYSE:SNN) Declares Dividend of $0.31

Smith & Nephew SNATS, Inc. (NYSE:SNN) announced a dividend on Tuesday, August 4th. Stockholders of record on Friday, October 2nd will be paid a dividend of 0.312 per share by the medical equipment provider on Friday, November 6th. This represents a dividend yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Smith & Nephew SNATS has a dividend payout ratio of 42.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Smith & Nephew SNATS to earn $2.48 per share next year, which means the company should continue to be able to cover its $0.93 annual dividend with an expected future payout ratio of 37.5%.

Smith & Nephew SNATS Trading Down 2.6%

Shares of SNN stock traded down $0.80 during trading hours on Wednesday, hitting $29.64. 216,198 shares of the company were exchanged, compared to its average volume of 1,188,779. Smith & Nephew SNATS has a one year low of $28.56 and a one year high of $38.79. The business’s 50-day simple moving average is $30.45 and its two-hundred day simple moving average is $32.18. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57.

Wall Street Analyst Weigh In

A number of research analysts have commented on SNN shares. Kepler Capital Markets downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Finally, Canaccord Genuity Group decreased their price objective on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a report on Monday, May 11th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $30.93.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.